What is TRIB's earnings growth forecast for 2026-2026?
(NASDAQ: TRIB) Trinity Biotech's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of N/A, and while it is not forecast to beat the US market's average forecast earnings growth rate of N/A.
Trinity Biotech's earnings in 2026 is -$36,479,000.
In 2026, TRIB is forecast to generate -$184,590,863 in earnings, with the lowest earnings forecast at -$177,352,006 and the highest earnings forecast at -$190,020,006.
What is TRIB's revenue growth forecast for 2026-2026?
(NASDAQ: TRIB) Trinity Biotech's forecast annual revenue growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of N/A, and while it is not forecast to beat the US market's average forecast revenue growth rate of N/A.
Trinity Biotech's revenue in 2026 is $49,409,000.
In 2026, TRIB is forecast to generate $29,195,493,655 in revenue, with the lowest revenue forecast at $28,050,572,335 and the highest revenue forecast at $30,054,184,645.
What is TRIB's forecast return on assets (ROA) for 2026-2026?
(NASDAQ: TRIB) forecast ROA is -185.27%, which is lower than the forecast US Diagnostics & Research industry average of 9.72%.
What is TRIB's Earnings Per Share (EPS) forecast for 2026-2026?
(NASDAQ: TRIB) Trinity Biotech's current Earnings Per Share (EPS) is -$1.50. In 2026, TRIB's EPS is forecast to hit -$0.50 (min: -$0.48, max: -$0.51).
What is TRIB's forecast return on equity (ROE) for 2026-2026?
(NASDAQ: TRIB) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.